Novo Nordisk A/S (NVO) Stock: Drops as Semaglutide Helps 40% of Children Exit Obesity Classification 

TLDR Semaglutide helped 40.4% of children move below the obesity threshold in STEP Young. NVO stock fell 1.92% as Novo Nordisk reported positive STEP Young trial results. STEP Young met its main goal with stronger BMI reductions than placebo at week 68. No new safety concerns emerged for growth or puberty in the STEP Young [...]

The post Novo Nordisk A/S (NVO) Stock: Drops as Semaglutide Helps 40% of Children Exit Obesity Classification  appeared first on Blockonomi.